Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Share-based Compensation (2016 - 2025)

Utah Medical Products has reported Share-based Compensation over the past 16 years, most recently at $111000.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $111000.0 for Q4 2025, up 56.34% from a year ago — trailing twelve months through Dec 2025 was $373000.0 (up 46.27% YoY), and the annual figure for FY2025 was $373000.0, up 46.27%.
  • Share-based Compensation for Q4 2025 was $111000.0 at Utah Medical Products, up from $94000.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for UTMD hit a ceiling of $111000.0 in Q4 2025 and a floor of $38000.0 in Q3 2022.
  • Median Share-based Compensation over the past 5 years was $52500.0 (2023), compared with a mean of $60100.0.
  • Peak annual rise in Share-based Compensation hit 78.26% in 2021, while the deepest fall reached 16.33% in 2021.
  • Utah Medical Products' Share-based Compensation stood at $43000.0 in 2021, then surged by 44.19% to $62000.0 in 2022, then increased by 16.13% to $72000.0 in 2023, then fell by 1.39% to $71000.0 in 2024, then soared by 56.34% to $111000.0 in 2025.
  • The last three reported values for Share-based Compensation were $111000.0 (Q4 2025), $94000.0 (Q3 2025), and $86000.0 (Q2 2025) per Business Quant data.